James J Berlanti
There is a relatively small segment of leaders in the business world; individuals with leadership and the ability to leverage their knowledge and education to achieve aggressive goals while building trust and relationships and rapport and motivating forward momentum to achieve goals.
Jim Berlanti, MD is one of those professionals, who throughout his career possess a proven record of success driving results through collaboration, partnerships, and relationships as both an Internist with his peers and a Medical Strategist in the healthcare industry. With enthusiasm Jim radiates a sincere passion for delivering value and benefits to agencies, clients and business units.
As the Chief Medical Officer for one of the world’s largest healthcare agencies, Jim created and led a scientific team and a global network of expert advisors, which consistently identified untapped opportunities through market analysis and led to the success of numerous category leaders including Crestor, Enbrel, Seroquel, Prilosec/Nexium and Ambien. Jim’s role was expanded to uncover insights across brands and agencies, worldwide, for the worlds largest healthcare communications network Publicis Healthcare. He was part of the global new business team G7.
He was part of the Saatchi/Pharmacia team that was instrumental in working with FDA and KOLs redefining a category, OAB, for Detrol, when Detrol did not meet it’s primary endpoint.. OAB was created specifically as a consumer driven term. OAB developed into a multi-billion dollar category.
In 2008, Saatchi and Saatchi were named “Agency of the Year”. As part of the Saatchi management team he also was part of the global new business team. Jim devoted 60-70 % of his time to new business pitches across all promotional venues. In 2009 Saatchi won 29 new business pitches.
Jim’s expertise and experience across virtually every therapeutic category is current as are the insights he has, he has the ability to see the commercial opportunity within evolving market dynamics, and he has an unmatched network of experts who will speak to him with more authenticity peer to peer because of their respect for him.
From an Internist’s perspective, Jim brings advanced medical knowledge and insight to the MD audiences, with the documented ability to communicate current and future medical trends, within the physician and pharmaceutical communities. He has expert insights into all the specialties, both at the KOL level, as well as the PCP and the community specialists, by market. He has the ability to speak about the disease states across categories. Jim has built a very large network of key opinion leaders and academic community physicians across many specialties and global marketplaces. He also has a working knowledge of FDA and other regulatory agencies.
Jim joined Havas World Wide in April of 2014 as SVP Medical Director. He worked on a new PCSK9 monoclonal antibody that is coming to market for hyperlipidemia. His other responsibilities included working as an internal consultant across the global network. He went on to work at Noven Pharmaceuticals, Harrison & Star and Ogilvy where he was part of the Agency/Client Xeljanz team, due to his category experience, having launched Enbrel and basically having touched every new entry into that space.
Jim holds a Bachelor of Arts in science from the College of the Holy Cross and a Doctor of Medicine from Mt. Sinai Icahn School of Medicine in New York City. After completing his residency in Internal Medicine at Mt. Sinai Icahn School of Medicine at Elmhurst, Jim served as a staff and faculty member at NYU/Bellevue Hospital Medical Center for two years. He then moved into Advertising.
With many key accomplishments, Jim has more than 27 year of success Agency side supporting customer centric agencies bridging the gap between agencies, physicians and pharmaceutical companies focusing on current and future product trends supported by successful communications assisting agencies in reaching and exceeding their revenue goals.
